Clinical Trial News and Research

RSS

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

5 Feb 2014

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that The Lancet has published the results of its Phase 2 clinical trial of its lead candidate, EMA401, in postherpetic neuralgia (PHN).

5 Feb 2014

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced today that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer's plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.

5 Feb 2014

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to standard antiepileptic drugs.

5 Feb 2014

New drug treatment effective against chronic pain caused by nerve damage post shingles

A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

5 Feb 2014

Randomized trial shows injecting anesthetic near nerve bundle reduces troublesome hot flashes

Injecting a little anesthetic near a nerve bundle in the neck cut troublesome hot flashes significantly, shows a new randomized, controlled trial published online today in Menopause, the journal of The North American Menopause Society (NAMS).

5 Feb 2014

FDA approves new artificial heart valve device that does not require major open surgery

An artificial heart valve device that does not require major open surgery has been approved by the Food and Drug Administration.

From Medtronic 5 Feb 2014

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.

4 Feb 2014

Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advanced breast cancer

Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.

4 Feb 2014

BBA supports 510(k) clearance of Kiva VCF Treatment System

Boston Biomedical Associates (BBA) is proud to have supported our client and colleagues at Benvenue Medical, Inc. during The Kiva® System as a Vertebral Augmentation Treatment or KAST trial, and recent 510(k) clearance of the Kiva® VCF Treatment System.

4 Feb 2014

Sanford Hospital starts clinical trial to study dissolving device in patients with CAD

Sanford Heart Hospital has started a clinical trial to study a dissolving device in patients with coronary artery disease. The ABSORB III clinical trial will investigate the safety and effectiveness of the Absorb Bioresorbable Vascular Scaffold (BVS) device, manufactured by global health care company Abbott.

4 Feb 2014

Blood pressure lowering linked with reduced risk for cognitive decline in patients with T2DM

Intensive blood pressure and cholesterol lowering was not associated with reduced risk for diabetes-related cognitive decline in older patients with long-standing type 2 diabetes mellitus, according to a study by Jeff D. Williamson, M.D., M.H.S., of the Wake Forest School of Medicine, Winston-Salem, N.C., and colleagues.

4 Feb 2014

Treating depression before onset of cardiovascular disease can cut risk of heart attack, stroke

Research led by Jesse C. Stewart, Ph.D., of the School of Science at Indiana University-Purdue University Indianapolis, is the first to find that treatment of depression before any apparent signs of cardiovascular disease can decrease the risk of future heart attacks and strokes by almost half.

4 Feb 2014

Researchers develop cardiac tissue from human stem cells to find cures for heart diseases

When it comes to finding cures for heart disease, scientists at Icahn School of Medicine at Mount Sinai are working to their own beat. They may have developed a tissue model for the human heart that can bridge the gap between animal models and human clinical trial patients.

4 Feb 2014

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India.

3 Feb 2014

Study describes new tack in treatment of lung adenocarcinomas

The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients, researchers at Dana-Farber Cancer Institute and other scientists report in a new study.

31 Jan 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.

31 Jan 2014

YODA Project enters an agreement with Johnson & Johnson to gain access to clinical trial data assets

In a move that promotes open science, the Yale University Open Data Access (YODA) Project has entered an agreement with Johnson & Johnson that will enable scientists around the world to gain access to the company's clinical trial data assets.

30 Jan 2014

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

AVEO Oncology today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.

30 Jan 2014

Clinical Trial News and Research

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

New drug treatment effective against chronic pain caused by nerve damage post shingles

Randomized trial shows injecting anesthetic near nerve bundle reduces troublesome hot flashes

FDA approves new artificial heart valve device that does not require major open surgery

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advanced breast cancer

BBA supports 510(k) clearance of Kiva VCF Treatment System

Sanford Hospital starts clinical trial to study dissolving device in patients with CAD

Blood pressure lowering linked with reduced risk for cognitive decline in patients with T2DM

Treating depression before onset of cardiovascular disease can cut risk of heart attack, stroke

Researchers develop cardiac tissue from human stem cells to find cures for heart diseases

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Study describes new tack in treatment of lung adenocarcinomas

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

YODA Project enters an agreement with Johnson & Johnson to gain access to clinical trial data assets

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer